Bicocca Open Archive

Logo unimib boa
MANTOVANI, LORENZO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.556
EU - Europa 13.114
AS - Asia 7.166
SA - Sud America 487
AF - Africa 91
OC - Oceania 45
Continente sconosciuto - Info sul continente non disponibili 37
Totale 43.496
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.211
IT - Italia 3.308
SG - Singapore 3.018
RU - Federazione Russa 2.318
DE - Germania 1.824
CN - Cina 1.676
IE - Irlanda 1.525
SE - Svezia 1.379
HK - Hong Kong 1.371
UA - Ucraina 685
GB - Regno Unito 559
BR - Brasile 417
FR - Francia 379
ID - Indonesia 323
CA - Canada 301
FI - Finlandia 255
AT - Austria 243
DK - Danimarca 182
IN - India 171
VN - Vietnam 165
NL - Olanda 164
TR - Turchia 135
IR - Iran 55
BE - Belgio 48
CH - Svizzera 41
AU - Australia 35
ES - Italia 32
PK - Pakistan 32
EU - Europa 30
MX - Messico 30
CZ - Repubblica Ceca 28
KR - Corea 26
BD - Bangladesh 23
IQ - Iraq 23
JP - Giappone 22
PL - Polonia 22
RO - Romania 22
ZA - Sudafrica 22
AR - Argentina 20
PH - Filippine 17
AE - Emirati Arabi Uniti 16
CL - Cile 14
NG - Nigeria 13
TW - Taiwan 13
PT - Portogallo 12
BG - Bulgaria 11
CO - Colombia 11
NO - Norvegia 11
AL - Albania 10
EG - Egitto 10
NZ - Nuova Zelanda 10
GR - Grecia 9
KE - Kenya 9
MA - Marocco 9
OM - Oman 9
ET - Etiopia 8
RS - Serbia 8
AZ - Azerbaigian 7
MY - Malesia 7
TH - Thailandia 7
UZ - Uzbekistan 7
VE - Venezuela 7
EC - Ecuador 6
MD - Moldavia 6
SA - Arabia Saudita 6
A2 - ???statistics.table.value.countryCode.A2??? 5
IL - Israele 5
LK - Sri Lanka 5
PE - Perù 5
GE - Georgia 4
HR - Croazia 4
JM - Giamaica 4
JO - Giordania 4
LT - Lituania 4
LU - Lussemburgo 4
MK - Macedonia 4
NP - Nepal 4
SD - Sudan 4
TN - Tunisia 4
BO - Bolivia 3
HN - Honduras 3
HU - Ungheria 3
KZ - Kazakistan 3
LV - Lettonia 3
NI - Nicaragua 3
SC - Seychelles 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
A1 - Anonimo 2
AM - Armenia 2
DZ - Algeria 2
GA - Gabon 2
GT - Guatemala 2
KG - Kirghizistan 2
MN - Mongolia 2
PS - Palestinian Territory 2
PY - Paraguay 2
SN - Senegal 2
SO - Somalia 2
UY - Uruguay 2
Totale 43.484
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.737
Fairfield 1.958
Singapore 1.953
Woodbridge 1.677
Chandler 1.434
Dublin 1.420
Hong Kong 1.353
Ashburn 1.211
Houston 1.204
Wilmington 1.165
Frankfurt am Main 1.155
Santa Clara 1.001
Seattle 859
Milan 804
Jacksonville 732
New York 711
Princeton 665
Cambridge 662
Dearborn 640
Altamura 302
Jakarta 295
Lawrence 292
Nanjing 263
Vienna 200
Shanghai 164
San Diego 155
Moscow 142
Beijing 138
Rome 132
Hangzhou 129
Helsinki 114
Nuremberg 107
Lachine 104
Council Bluffs 102
Andover 100
Dong Ket 100
London 98
Shenyang 94
Guangzhou 92
Nanchang 92
Saint Petersburg 87
Toronto 86
Boardman 75
Fremont 75
Hebei 70
Jinan 70
Tianjin 64
Menlo Park 63
Norwalk 59
Jiaxing 57
Los Angeles 55
Falls Church 53
Ottawa 51
Changsha 50
Bologna 49
Ningbo 44
Redmond 44
Zhengzhou 42
São Paulo 41
Brussels 37
Munich 37
Washington 36
Lissone 35
Turin 33
Perugia 32
Lappeenranta 30
Pune 29
Verona 29
Taizhou 28
Florence 27
Hefei 27
Palermo 27
Chicago 25
Kunming 25
Paris 25
Monza 23
Dallas 22
Düsseldorf 22
Mountain View 22
Naples 21
Parma 21
Bonndorf 19
The Dalles 19
Genoa 18
Brno 16
Bergamo 15
Boston 15
Edmonton 15
Huizen 15
Legnano 15
Napoli 15
Pavia 15
Phoenix 15
Carate Brianza 14
Kocaeli 14
Nürnberg 14
Padova 14
Belo Horizonte 13
Brescia 13
Duncan 13
Totale 29.591
Salva come PNG Salva come JPEG
Nome #
Costi dell’infarto miocardico acuto: analisi di dati sanitari amministrativi 823
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry 403
Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women 359
Administrative databases as a tool for identifying healthcare demand and costs in an over-one million population 357
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 350
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study 325
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 316
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors 307
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review 290
Two-year outcomes of patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF 261
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 258
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study 252
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study) 247
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 246
The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand? 244
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017 236
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 230
Magnitude and time-course of excess mortality during COVID-19 outbreak: population-based empirical evidence from highly impacted provinces in northern Italy 223
Occupational exposure in the lombardy region (Italy) to sars-cov-2 infection: Results from the mustang–occupation–covid-19 study 214
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 212
Global, regional, and national burden of suicide mortality 1990 to 2016: Systematic analysis for the Global Burden of Disease Study 2016 208
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 207
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 206
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 203
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 203
Treatment of venous thromboembolism with tinzaparin in oncological patients 202
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 200
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors 196
Health Related Quality of Life in the Major Liver Conditions 195
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 194
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 194
Health related quality of life in chronic liver diseases 194
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 193
Cost-Effectiveness and Cost-Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study 191
The impact of liver disease on the health-related quality of life 191
Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry 191
Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry 189
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 187
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 185
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 185
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 185
Sustainability of the Italian National Health Service 184
Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity 184
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis 184
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 182
Estimates of the initial impact of the COVID-19 epidemic on overall mortality: evidence from Italy 182
Medical Costs And Resources Consumption In Patients With Atrial Fibrillation: An Italian Observational Study 182
Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting 181
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America 181
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 180
Economic Burden of Urticaria Requiring Hospitalization: Analysis from an Administrative Database 179
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 179
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 178
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 178
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 178
Costs and effectiveness of influenza vaccination: A systematic review 178
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 177
COVID-19 outbreak impact on anticoagulants utilization: an interrupted time-series analysis using healthcare administrative databases 175
Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 174
Impatto clinico ed economico della gestione dei rialzi pressori in gravidanza in regime di pronto soccorso: il possibile ruolo dei marcatori biochimici 174
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 173
The socioeconomic burden of patients affected by hemophilia with inhibitors 172
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 171
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 171
Il burden delle polmoniti: analisi dai database amministrativi (DENALI) della regione Lombardia. 170
The Burden of Severe Hypoglicaemias and Diabetes Ketoacidosis: A Population-Based Study 169
Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?: The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation 168
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 167
Implantable Cardioverter Defibrillator in Italy from 2000 to 2008: a population-based analysis using health administrative databases. 166
Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: Barriers to and strategies for optimal implementation 166
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 165
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 164
Persistence and adherence to hypolipemic therapy in real practice: Results of a large administrative database 163
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 162
Economic Burden Of Stroke: Analysis From An Administrative Database 162
Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases 161
Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists 161
Cost and outcomes after first acute myocardial infarction: study on 12049 individuals using administrative databases 160
Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: Co-medication interactions 160
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 159
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 157
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study) 157
New pharmacoeconomic option in uremic anemia management [3] 156
Resource utilization and costs for patients with inflammatory bowel diseases in italy: a population-based assessment 153
The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities 153
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 152
Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation 152
Utilization of disease modifying agents in multiple sclerosis: from an Italian administrative database. 151
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 151
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 150
The Economic Impact of The use of Implantable Cardioverter Defibrillator In Primary Prevention 150
Epidemiology and Direct Health Care Costs of Diabetic Retinopathy: Results From a Population-Based Study 149
The economic impact of air pollution: a European assessment 149
The Cost Of Illness Of Atrial Fibrillation In Italy: A Cohort Of Hospitalized Patients 148
Burden of diabetes mellitus estimated with a longitudinal population-based study using administrative databases 148
Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A 147
Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015 147
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 147
Implantable cardioverter defibrillator (ICD) in Italy from 2000 to 2008: a population-based analysis using health administrative databases 146
Epidemiologic And Economic Burden Attributable To Atrial Fibrillation From Administrative Data 145
Totale 19.980
Salva come PNG Salva come JPEG
Categoria #
all - tutte 183.344
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 183.344
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020761 0 0 0 0 0 0 0 0 0 323 318 120
2020/20216.836 668 445 713 524 590 615 699 682 567 512 363 458
2021/20223.998 321 391 400 360 275 301 196 248 234 295 280 697
2022/20236.447 781 1.873 536 518 455 977 74 355 480 93 182 123
2023/20245.455 171 247 185 271 681 1.299 859 195 525 158 235 629
2024/202510.559 811 1.811 751 740 1.251 943 818 477 1.648 1.309 0 0
Totale 45.580